Almirall, S.A. Q3 2025 Earnings Recap

Almirall reported strong financial results for the first nine months of 2025, bolstered by impressive sales growth in its medical dermatology portfolio, particularly from Ebglyss and Ilumetri.

Key Takeaways

• Net sales of Ilumetri reached EUR 171 million, representing a 12% year-on-year growth, with peak sales expected to exceed EUR 300 million.
• Ebglyss sales nearly quadrupled to EUR 75.5 million, underscoring its success as a leading atopic dermatitis treatment in a rapidly expanding market.
• Strong momentum in newly launched European markets boosts confidence in Almirall’s product positioning and growth trajectory.
• Ongoing clinical trials and collaborations, particularly in atopic dermatitis, are expected to enhance the company's competitive edge and growth potential.
• Almirall reiterated its mid-term guidance, reflecting confidence in its product pipeline and market strategies.